Efficacy of mitoxantrone against various neoplasms in dogs

Gregory K. Ogilvie From The Comparative Oncology Unit, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Ogilvie, Obradovich, Elmslie, Vail, Straw, Dickinson, Cooper, Withrow) and Tufts University School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 (Moore).

Search for other papers by Gregory K. Ogilvie in
Current site
Google Scholar
PubMed
Close
 DVM
,
Joyce E. Obradovich From The Comparative Oncology Unit, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Ogilvie, Obradovich, Elmslie, Vail, Straw, Dickinson, Cooper, Withrow) and Tufts University School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 (Moore).

Search for other papers by Joyce E. Obradovich in
Current site
Google Scholar
PubMed
Close
 DVM
,
Robyn E. Elmslie From The Comparative Oncology Unit, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Ogilvie, Obradovich, Elmslie, Vail, Straw, Dickinson, Cooper, Withrow) and Tufts University School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 (Moore).

Search for other papers by Robyn E. Elmslie in
Current site
Google Scholar
PubMed
Close
 DVM
,
David M. Vail From The Comparative Oncology Unit, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Ogilvie, Obradovich, Elmslie, Vail, Straw, Dickinson, Cooper, Withrow) and Tufts University School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 (Moore).

Search for other papers by David M. Vail in
Current site
Google Scholar
PubMed
Close
 DVM
,
A. S. Moore From The Comparative Oncology Unit, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Ogilvie, Obradovich, Elmslie, Vail, Straw, Dickinson, Cooper, Withrow) and Tufts University School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 (Moore).

Search for other papers by A. S. Moore in
Current site
Google Scholar
PubMed
Close
 MVSc
,
Rodney C. Straw From The Comparative Oncology Unit, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Ogilvie, Obradovich, Elmslie, Vail, Straw, Dickinson, Cooper, Withrow) and Tufts University School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 (Moore).

Search for other papers by Rodney C. Straw in
Current site
Google Scholar
PubMed
Close
 BVSc
,
Krista Dickinson From The Comparative Oncology Unit, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Ogilvie, Obradovich, Elmslie, Vail, Straw, Dickinson, Cooper, Withrow) and Tufts University School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 (Moore).

Search for other papers by Krista Dickinson in
Current site
Google Scholar
PubMed
Close
,
Mary F. Cooper From The Comparative Oncology Unit, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Ogilvie, Obradovich, Elmslie, Vail, Straw, Dickinson, Cooper, Withrow) and Tufts University School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 (Moore).

Search for other papers by Mary F. Cooper in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Stephen J. Withrow From The Comparative Oncology Unit, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 (Ogilvie, Obradovich, Elmslie, Vail, Straw, Dickinson, Cooper, Withrow) and Tufts University School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 (Moore).

Search for other papers by Stephen J. Withrow in
Current site
Google Scholar
PubMed
Close
 DVM

Click on author name to view affiliation information

Summary

One hundred twenty-six dogs with histologically confirmed, measurable malignant tumors were evaluated in a prospective study to determine the response to the antineoplastic drug mitoxantrone. Ninety-five dogs had been refractory to one or more treatment modalities (surgery, n = 57; chemotherapy other than mitoxantrone, n = 37; radiation, n = 4; whole body hyperthermia, n = 1). The extent of neoplastic disease was determined immediately before each dose of mitoxantrone was administered (1 to 10 doses, 2.5 to 5 mg/m2 of body surface area, iv) 21 days apart. Each dog was treated with mitoxantrone until the dog developed progressive disease or until the dog's quality of life diminished to an unacceptable level as determined by the owner or attending veterinarian.

A partial or complete remission (>50% volume reduction) was obtained in 23% (29/126) of all dogs treated. Tumors in which there was a partial or complete remission included lymphoma (11/32), squamous cell carcinoma (4/9), fibrosarcoma (2/9), thyroid carcinoma (1/10), transitional cell carcinoma (1/6), mammary adenocarcinoma (1/6), hepatocellular carcinoma (1/4), renal adenocarcinoma (1/1), rectal carcinoma (1/1), chondrosarcoma (1/2), oral malignant melanoma (1/12), cutaneous malignant melanoma (1/1), myxosarcoma (1/1), mesothelioma (1/1), and hemangiopericytoma (1/1).

Our results indicated that mitoxantrone induces measurable regression in various malignant tumors in dogs.

Summary

One hundred twenty-six dogs with histologically confirmed, measurable malignant tumors were evaluated in a prospective study to determine the response to the antineoplastic drug mitoxantrone. Ninety-five dogs had been refractory to one or more treatment modalities (surgery, n = 57; chemotherapy other than mitoxantrone, n = 37; radiation, n = 4; whole body hyperthermia, n = 1). The extent of neoplastic disease was determined immediately before each dose of mitoxantrone was administered (1 to 10 doses, 2.5 to 5 mg/m2 of body surface area, iv) 21 days apart. Each dog was treated with mitoxantrone until the dog developed progressive disease or until the dog's quality of life diminished to an unacceptable level as determined by the owner or attending veterinarian.

A partial or complete remission (>50% volume reduction) was obtained in 23% (29/126) of all dogs treated. Tumors in which there was a partial or complete remission included lymphoma (11/32), squamous cell carcinoma (4/9), fibrosarcoma (2/9), thyroid carcinoma (1/10), transitional cell carcinoma (1/6), mammary adenocarcinoma (1/6), hepatocellular carcinoma (1/4), renal adenocarcinoma (1/1), rectal carcinoma (1/1), chondrosarcoma (1/2), oral malignant melanoma (1/12), cutaneous malignant melanoma (1/1), myxosarcoma (1/1), mesothelioma (1/1), and hemangiopericytoma (1/1).

Our results indicated that mitoxantrone induces measurable regression in various malignant tumors in dogs.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 271 271 119
PDF Downloads 76 76 13
Advertisement